ACADIA Pharmaceuticals (ACAD) Releases Earnings Results, Misses Expectations By $-0.03 EPS

ACADIA Pharmaceuticals (ACAD) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.45 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $-0.42. Analysts expectations of $.22 million. During the same quarter in the previous year, the company posted $-0.40 EPS.

Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by Leerink Partners to ” Mkt Perform” on May 3, 2016. Company shares were Reiterated by Piper Jaffray on Mar 30, 2016 to “Overweight”, Firm has raised the Price Target to $ 44 from a previous price target of $39 .BofA/Merrill Initiated ACADIA Pharmaceuticals on Feb 8, 2016 to “Buy”, Price Target of the shares are set at $40.

ACADIA Pharmaceuticals closed down -2.47 points or -8.23% at $27.53 with 47,25,046 shares getting traded on Wednesday. Post opening the session at $29.03, the shares hit an intraday low of $27.19 and an intraday high of $29.65 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Mar 4, 2016, Glenn Baity (EVP AND GC) sold 7,000 shares at $20.80 per share price. According to the SEC, on Feb 19, 2015, Uli Hacksell (CEO) sold 30,000 shares at $34.30 per share price.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Company’s drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinson’s disease psychosis Alzheimer’s disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.

ACADIA Pharmaceuticals

Leave a Reply

ACADIA Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on ACADIA Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.